Welcome to our dedicated page for Aclarion news (Ticker: ACON), a resource for investors and traders seeking the latest updates and insights on Aclarion stock.
Aclarion, Inc. develops healthcare technology for chronic low back pain through Nociscan, a cloud-based SaaS platform that uses magnetic resonance spectroscopy, biomarkers, signal processing and augmented intelligence algorithms to help physicians evaluate painful and nonpainful lumbar discs.
Company news commonly covers Nociscan adoption, clinical-site additions, commercial agreements with spine practices and academic medical centers, reimbursement activity, intellectual-property updates for AI-enabled workflows, and operating results. Updates also include capital actions and governance items tied to Aclarion’s Nasdaq-listed common stock and warrants.
Summary not available.
Aclarion (Nasdaq: ACON) launched a Market Access Program with PRIA Healthcare to advance reimbursement and U.S. commercial adoption of its AI-powered Nociscan platform for chronic low back pain.
The partnership targets payer engagement, prior authorization support, appeals management, and builds on payer approvals already achieved with major UK insurers.
Aclarion (Nasdaq: ACON) announced that its Board unanimously rejected Echo Lake Capital’s unsolicited public proposal to acquire the company at $4.00 per share. The Board believes the offer undervalues Aclarion, relies on its cash to finance the acquisition, and would disproportionately benefit Echo Lake. The Board remains open to proposals that appropriately reflect Aclarion’s intrinsic value, strategic assets and long-term potential.
Aclarion (Nasdaq: ACON) reported that stockholders approved all proposals at the 2026 annual meeting held June 4, 2026. Approvals covered electing seven directors through the 2027 meeting, ratifying Haynie & Company as auditor, and amending the 2022 equity incentive plan.
Aclarion highlighted 196% year-over-year growth in Q1 2026 Nociscan scan volumes, expanded insurance coverage in the United Kingdom, and progress in its United States reimbursement strategy for its AI-driven chronic low back pain assessment technology.
Aclarion (Nasdaq: ACON) entered an agreement with the Institute of Neuro Innovation (INI) in Los Angeles, expanding access to its Nociscan platform for chronic low back pain patients.
The collaboration will generate real-world evidence combining Nociscan’s pain-related chemical biomarker data with SPECT-CT bone metabolic information, supporting Aclarion’s scalable growth strategy and payer and provider adoption. Nociscan is described as a SaaS tool that helps distinguish painful from nonpainful lumbar discs and has demonstrated a 97% surgical success rate when all Nociscan-positive discs are treated.
Aclarion (Nasdaq:ACON) reported that its Nociscan MRS technology was used in an NIH-funded, ISSLS Best Paper Award study on chronic low back pain with Modic type 1 changes.
By measuring intradiscal propionic acid, researchers identified immune-linked patient subgroups, suggesting potential Nociscan uses beyond surgical decision support in precision spine care.
Aclarion (Nasdaq: ACON) responded to Echo Lake Capital’s unsolicited offer to acquire the company for $4.00 per share in cash plus contingent value rights. The Board will carefully evaluate the proposal and has also authorized a share repurchase program, citing conviction in Aclarion’s long-term opportunity.
Summary not available.
Aclarion (Nasdaq: ACON, ACONW) added Lanman Spinal Neurosurgery in Beverly Hills as the first private-practice site for its 300-patient CLARITY randomized trial of Nociscan for discogenic chronic low back pain. The trial's primary endpoint is 12-month change in 100mm VAS Back; early interim results are expected to be publicly disclosed in Q4 2026.
Nociscan is described as a SaaS MR spectroscopy solution that quantifies chemical biomarkers and is reported to show a 97% surgical success rate when all Nociscan-positive discs are treated.
Aclarion (Nasdaq: ACON, ACONW) granted an inducement stock option to Daniel Keefe, its new Commercial Director, Western U.S., to purchase 17,000 shares on May 5, 2026. The option exercise price is $3.20 per share, equal to the closing price on the grant date.
One-fourth vests after one year; remaining options vest monthly over three years. The option term is ten years and was granted under Nasdaq Listing Rule 5635(c)(4) as an inducement material to Mr. Keefe joining the company.